The determinants of pharmaceutical research and development expenditures
AbstractSince the late 1970s, pharmaceutical R&D has grown at a rapid rate relative to sales and other variables. In this paper, we examine the determinants of pharmaceutical R&D using a pooled data sample of 11 major drug firms over the period 1974 to 1994. We find that expected returns and cash flows are important explanatory variables of firm research intensities during this period. This is consistent with our results for an earlier sample period characterized by very different growth patterns on R&D.
Download InfoIf you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
As the access to this document is restricted, you may want to look for a different version under "Related research" (further below) or search for a different version of it.
Bibliographic InfoArticle provided by Springer in its journal Journal of Evolutionary Economics.
Volume (Year): 10 (2000)
Issue (Month): 1 ()
Contact details of provider:
Web page: http://link.springer.de/link/service/journals/00191/index.htm
Find related papers by JEL classification:
- L65 - Industrial Organization - - Industry Studies: Manufacturing - - - Chemicals; Rubber; Drugs; Biotechnology
- O31 - Economic Development, Technological Change, and Growth - - Technological Change; Research and Development; Intellectual Property Rights - - - Innovation and Invention: Processes and Incentives
- O33 - Economic Development, Technological Change, and Growth - - Technological Change; Research and Development; Intellectual Property Rights - - - Technological Change: Choices and Consequences; Diffusion Processes
You can help add them by filling out this form.
CitEc Project, subscribe to its RSS feed for this item.
- Yang, Chih-Hai & Tseng, Yu-Hsuan & Chen, Chiang-Ping, 2012. "Environmental regulations, induced R&D, and productivity: Evidence from Taiwan's manufacturing industries," Resource and Energy Economics, Elsevier, vol. 34(4), pages 514-532.
- Jörg Mahlich & Thomas Roediger-Schluga, 2006.
"The Determinants of Pharmaceutical R&D Expenditures: Evidence from Japan,"
Review of Industrial Organization,
Springer, vol. 28(2), pages 145-164, 03.
- Mahlich, Jörg C. & Roediger-Schluga, Thomas, 2006. "The Determinants of Pharmaceutical R&D Expenditures: Evidence from Japan," MERIT Working Papers 015, United Nations University - Maastricht Economic and Social Research Institute on Innovation and Technology (MERIT).
- Toole, Andrew A., 2005. "Does Public Scientific Research Complement Industry R&D Investment? The Case of NIH Supported Basic and Clinical Research and Pharmaceutical Industry R&D," ZEW Discussion Papers 05-75, ZEW - Zentrum für Europäische Wirtschaftsforschung / Center for European Economic Research.
- Rodrigo Cerda, 2007. "Endogenous innovations in the pharmaceutical industry," Journal of Evolutionary Economics, Springer, vol. 17(4), pages 473-515, August.
- John A. Vernon, 2005. "Examining the link between price regulation and pharmaceutical R&D investment," Health Economics, John Wiley & Sons, Ltd., vol. 14(1), pages 1-16.
- Patricia M. Danzon & Eric L. Keuffel, 2013. "Regulation of the Pharmaceutical-Biotechnology Industry," NBER Chapters, in: Economic Regulation and Its Reform: What Have We Learned?, pages 407-484 National Bureau of Economic Research, Inc.
- Bakker, Gerben, 2013.
"Money for nothing: How firms have financed R&D-projects since the Industrial Revolution,"
Elsevier, vol. 42(10), pages 1793-1814.
- Gerben Bakker, 2013. "Money for nothing: how firms have financed R&D-projects since the Industrial Revolution," Economic History Working Papers 54518, London School of Economics and Political Science, Department of Economic History.
- Alex Coad & Rekha Rao, 2010.
"Firm growth and R&D expenditure,"
Economics of Innovation and New Technology,
Taylor & Francis Journals, vol. 19(2), pages 127-145.
- Bastian Rake, 2012.
"Determinants of Pharmaceutical Innovation: The Role of Technological Opportunities Revisited,"
Jena Economic Research Papers
2012-018, Friedrich-Schiller-University Jena, Max-Planck-Institute of Economics.
- Bastian Rake, 2013. "Determinants of Pharmaceutical Innovation: The Role of Technological Opportunities Revisited," DRUID Working Papers 13-03, DRUID, Copenhagen Business School, Department of Industrial Economics and Strategy/Aalborg University, Department of Business Studies.
- Thomas A. Abbott & John A. Vernon, 2005. "The Cost of US Pharmaceutical Price Reductions: A Financial Simulation Model of R&D Decisions," NBER Working Papers 11114, National Bureau of Economic Research, Inc.
- John Vernon & Joseph Golec & J. Stevens, 2010. "Comparative Effectiveness Regulations and Pharmaceutical Innovation," PharmacoEconomics, Springer, vol. 28(10), pages 877-887, October.
- Balconi, Margherita & Brusoni, Stefano & Orsenigo, Luigi, 2010.
"In defence of the linear model: An essay,"
Elsevier, vol. 39(1), pages 1-13, February.
- William Kingston, 2004. "Nelson's Concerns About Intellectual Property," Levine's Working Paper Archive 122247000000000461, David K. Levine.
- Rutger P. Daems PhD & Edith L. Maes DBA, 2013. "Pharmaceutical Portfolio Management: Global Disease Burden and Corporate Performance Metrics," Working Papers 2013/07, Maastricht School of Management.
- Henry Grabowski & John Vernon & Joseph DiMasi, 2003.
"Returns on R&D for 1990s New Drug Introductions,"
Levine's Working Paper Archive
618897000000000666, David K. Levine.
- Ramesh Govindaraj & Gnanaraj Chellaraj, 2002. "The Indian Pharmaceutical Sector : Issues and Options for Health Sector Reform," World Bank Publications, The World Bank, number 15231, July.
- repec:ebl:ecbull:v:6:y:2008:i:36:p:1-8 is not listed on IDEAS
- Barrenho, E & Smith, PC & Miraldo, M, 2013. "The determinants of attrition in drug development: a duration analysis," Working Papers 12204, Imperial College, London, Imperial College Business School.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Guenther Eichhorn) or (Christopher F Baum).
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If references are entirely missing, you can add them using this form.
If the full references list an item that is present in RePEc, but the system did not link to it, you can help with this form.
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your profile, as there may be some citations waiting for confirmation.
Please note that corrections may take a couple of weeks to filter through the various RePEc services.